ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
87.9%
25M of 28M shares
Institutional holders
135
20 new, 8 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Voting Shares Irrevocable Trust | 3,303,640 | 11.63% | 13G (passive) amendment | Dec 31, 2025 |
| ARK Investment Management LLC | 2,947,556 | 10.37% | 13G (passive) amendment | Apr 30, 2026 |
| Balyasny Asset Management L.P. | 2,183,985 | 8.04% | 13G (passive) | Sep 30, 2025 |
| BlackRock, Inc. | 2,104,537 | 7.80% | 13G (passive) amendment | Mar 31, 2025 |
| Amova Asset Management Americas, Inc. | 1,947,835 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Amova Asset Management Co., Ltd. | 1,947,835 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Nikko Asset Management Americas, Inc. | 1,926,084 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Sumitomo Mitsui Trust Group, Inc. | 1,926,084 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Catherine D. Wood | 1,715,040 | 6.32% | 13G (passive) amendment | Jun 30, 2025 |
| Federated Hermes, Inc. | 1,678,069 | 5.90% | 13G (passive) amendment | Sep 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 3,303,640 | 11.62% | $22.20M | – | 0.03% |
| ARK Investment Management LLC | 2,901,635 | 10.21% | $19.50M | +132,117 | 0.13% |
| BlackRock, Inc. | 2,614,012 | 9.20% | $17.57M | +731 | 0.00% |
| Sumitomo Mitsui Trust Holdings, Inc. | 1,963,123 | 6.91% | $13.19M | −325,812 | 0.01% |
| Nikko Asset Management Americas, Inc. | 1,960,458 | 6.90% | $13.14M | −328,477 | 0.17% |
| Vanguard Capital Management LLC | 1,114,956 | 3.92% | $7.49M | +7,936 | 0.00% |
| Two Sigma Investments, LP | 1,091,137 | 3.84% | $7.33M | +9,353 | 0.01% |
| Vanguard Portfolio Management LLC | 951,575 | 3.35% | $6.39M | −26,347 | 0.00% |
| Geode Capital Management, LLC | 693,660 | 2.44% | $4.66M | +32,732 | 0.00% |
| Aqr Capital Management LLC | 675,014 | 2.37% | $4.54M | +513,736 | 0.00% |
| Jacobs Levy Equity Management, Inc | 647,511 | 2.28% | $4.35M | +448,783 | 0.02% |
| State Street Corp | 569,598 | 2.00% | $3.83M | +25,735 | 0.00% |
| UBS Group AG | 490,632 | 1.73% | $3.30M | +32,355 | 0.00% |
| D. E. Shaw & Co., Inc. | 392,358 | 1.38% | $2.64M | +140,324 | 0.00% |
| Empire Life Investments Inc. | 366,217 | 1.29% | $2.46M | −17,276 | 0.14% |
| Hennion & Walsh Asset Management, Inc. | 346,207 | 1.22% | $2.33M | +66,528 | 0.07% |
| Millennium Management LLC | 336,996 | 1.19% | $2.26M | −141,561 | 0.00% |
| Goldman Sachs Group Inc | 309,863 | 1.09% | $2.08M | +111,182 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 261,789 | 0.92% | $1.76M | +66,929 | 0.00% |
| Charles Schwab Investment Management Inc | 231,628 | 0.81% | $1.56M | +15,128 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 135 | 25M | 87.9% | 20 / 56 | 40 / 8 | 3M | 2M |
| Q1 2026 | 124 | 24M | 85.5% | 28 / 47 | 36 / 23 | 5M | 3M |
| Q4 2025 | 120 | 24M | 83.6% | 28 / 35 | 38 / 42 | 5M | 7M |
| Q3 2025 | 136 | 26M | 91.7% | 22 / 50 | 39 / 28 | 3M | 3M |
| Q2 2025 | 143 | 26M | 91.1% | 26 / 50 | 39 / 26 | 2M | 3M |
| Q1 2025 | 144 | 27M | 93.6% | 22 / 46 | 49 / 24 | 2M | 2M |
| Q4 2024 | 147 | 27M | 93.8% | 15 / 55 | 47 / 31 | 3M | 3M |
| Q3 2024 | 164 | 27M | 93.3% | 24 / 57 | 49 / 30 | 6M | 3M |
| Q2 2024 | 171 | 27M | 93.4% | 35 / 45 | 65 / 40 | 3M | 5M |
| Q1 2024 | 179 | 29M | 100.0% | 33 / 55 | 62 / 18 | 5M | 2M |
| Q4 2023 | 165 | 26M | 92.6% | 36 / 53 | 54 / 14 | 3M | 2M |
| Q3 2023 | 145 | 25M | 88.4% | 22 / 51 | 52 / 20 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ARCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| ARK Genomic Revolution ETF | 2,741,123 | 9.64% | $15.79M | 1.01% | Jul 31, 2026 |
| Federated Hermes Kaufmann Fund | 1,962,580 | 6.90% | $11.30M | 0.23% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 1,186,700 | 4.18% | $6.84M | 0.24% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 797,154 | 2.80% | $5.36M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 712,395 | 2.51% | $4.79M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 293,104 | 1.03% | $1.97M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 292,439 | 1.03% | $1.68M | 0.00% | Jul 31, 2026 |
| Vanguard Explorer Fund | 285,663 | 1.01% | $1.65M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 254,094 | 0.89% | $1.71M | 0.01% | Jun 30, 2026 |
| Vanguard Strategic Small-Cap Equity Fund | 253,764 | 0.89% | $1.71M | 0.05% | Jun 30, 2026 |
| iShares Biotechnology ETF | 183,754 | 0.65% | $1.23M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 138,170 | 0.49% | $1.09M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 136,565 | 0.48% | $1.08M | 0.01% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 135,078 | 0.48% | $1.07M | 0.02% | May 29, 2026 |
| Schwab U.S. Small-Cap ETF | 131,117 | 0.46% | $1.04M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joseph E. Payne | President and CEO, Director | 1,480,097 | 5.21% | Dec 19, 2025 |
| Andy Sassine | Chief Financial Officer, Director | 221,764 | 0.78% | Aug 20, 2025 |
| Dennis Mulroy | Chief Financial Officer | – | – | May 7, 2026 |
| Pad Chivukula | Chief Scientific Officer & COO | 435,334 | 1.53% | Dec 19, 2025 |
| Lance Kurata | Chief Legal Officer | – | – | Dec 19, 2025 |
| Joseph Roberts | Controller | 2,201 | 0.01% | Dec 19, 2025 |
| Jing L. Marantz | Director | 3,131 | 0.01% | Jun 15, 2026 |
| Magda Marquet | Director | 28,073 | 0.10% | Jun 15, 2026 |
| Peter C. Farrell | Director | 98,696 | 0.35% | Jun 15, 2026 |
| Moncef Slaoui | Director | – | – | Jun 15, 2026 |
| Edward W. Holmes | Director | 3,131 | 0.01% | Jun 15, 2026 |
| John Markels | Director | 3,131 | 0.01% | Jun 15, 2026 |
| James F. Barlow | Director | 13,131 | 0.05% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2025 | Buy | +1,238 | $16.56 | $20.50K | 221,764 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2025 | Buy | −1,238 | $16.56 | $20.50K | 221,764 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 15, 2024 | Sale(10b5-1 plan) | −12,000 | $20.76 | $249.12K | 435,334 |
| Magda Marquet Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| Edward W. Holmes Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| John Markels Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| James F. Barlow Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 13,131 |
| Peter C. Farrell Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 55,741 |
| Jing L. Marantz Director | Jun 14, 2024 | Option exercise | +3,131 | – | – | 3,131 |
| Andy Sassine Chief Financial Officer, Director | Jun 12, 2024 | Sale | −50,000 | $32.03 | $1.60M | 220,526 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 5, 2024 | Sale(10b5-1 plan) | −114 | $45.00 | $5.13K | 447,334 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 3, 2024 | Sale(10b5-1 plan) | −26,000 | $40.01 | $1.04M | 447,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 25, 2024 | Sale(10b5-1 plan) | −17,435 | $35.02 | $610.57K | 473,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 19, 2024 | Sale(10b5-1 plan) | −8,565 | $35.01 | $299.86K | 490,883 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 1, 2023 | Sale(10b5-1 plan) | −5,000 | $18.72 | $93.60K | 499,448 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 2, 2023 | Sale(10b5-1 plan) | −5,000 | $25.61 | $128.05K | 504,448 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 1, 2023 | Sale(10b5-1 plan) | −5,000 | $31.45 | $157.25K | 509,448 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2023 | Award | +1,223 | $17.37 | $21.24K | 270,526 |
| Pad Chivukula Chief Scientific Officer & COO | Aug 1, 2023 | Sale(10b5-1 plan) | −5,000 | $34.91 | $174.55K | 514,448 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +1,437 | $4.99 | $7.17K | 6,887 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +4,500 | $9.04 | $40.68K | 5,450 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Option exercise | +1,031 | $14.12 | $14.56K | 7,918 |
| Keith C. Kummerfeld See Remarks | Jul 14, 2023 | Sale(10b5-1 plan) | −6,968 | $35.00 | $243.88K | 950 |
| Pad Chivukula Chief Scientific Officer & COO | Jul 14, 2023 | Sale(10b5-1 plan) | −25,000 | $35.01 | $875.25K | 519,448 |
| Pad Chivukula Chief Scientific Officer & COO | Jul 3, 2023 | Sale(10b5-1 plan) | −5,000 | $28.75 | $143.75K | 544,448 |
| Pad Chivukula Chief Scientific Officer & COO | Jun 1, 2023 | Sale(10b5-1 plan) | −5,000 | $27.16 | $135.80K | 549,448 |
| Pad Chivukula Chief Scientific Officer & COO | May 11, 2023 | Sale(10b5-1 plan) | −7,925 | $30.24 | $239.65K | 554,448 |
| Pad Chivukula Chief Scientific Officer & COO | May 10, 2023 | Sale(10b5-1 plan) | −17,075 | $30.00 | $512.25K | 562,373 |
| Pad Chivukula Chief Scientific Officer & COO | May 1, 2023 | Sale(10b5-1 plan) | −5,000 | $25.93 | $129.65K | 579,448 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +1,031 | $14.12 | $14.56K | 1,981 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Sale(10b5-1 plan) | −6,968 | $28.18 | $196.36K | 950 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +1,437 | $4.99 | $7.17K | 7,918 |
| Keith C. Kummerfeld See Remarks | Apr 18, 2023 | Option exercise | +4,500 | $9.04 | $40.68K | 6,481 |
| Pad Chivukula Chief Scientific Officer & COO | Apr 3, 2023 | Sale(10b5-1 plan) | −5,000 | $25.38 | $126.90K | 584,448 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 6, 2023 | Sale(10b5-1 plan) | −5,000 | $16.07 | $80.35K | 589,448 |
| Magda Marquet Director | Dec 15, 2022 | Buy | +2,222 | $18.00 | $40.00K | 24,942 |
| Joseph E. Payne President and CEO, Director | Nov 23, 2022 | Buy | +5,000 | $16.51 | $82.55K | 1,480,097 |
| Andy Sassine Chief Financial Officer, Director | Aug 15, 2022 | Award | +1,068 | $18.42 | $19.67K | 269,303 |
| Pad Chivukula Chief Scientific Officer & COO | Jan 4, 2022 | Sale(10b5-1 plan) | −8,100 | $40.00 | $324.00K | 594,448 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 16, 2021 | Sale(10b5-1 plan) | −3,633 | $40.00 | $145.32K | 602,548 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 8, 2021 | Sale(10b5-1 plan) | −6,367 | $40.00 | $254.68K | 606,181 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 1, 2021 | Sale(10b5-1 plan) | −10,000 | $44.41 | $444.10K | 612,548 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 1, 2021 | Sale(10b5-1 plan) | −10,000 | $44.36 | $443.60K | 622,548 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 1, 2021 | Sale(10b5-1 plan) | −10,000 | $55.86 | $558.60K | 632,548 |
| Pharmaceutical Inc. Ultragenyx Director | Aug 11, 2021 | Sale | −75,000 | $45.83 | $3.44M | 1,400,000 |
| Pharmaceutical Inc. Ultragenyx Director | Aug 10, 2021 | Sale | −725,000 | $55.44 | $40.19M | 1,475,000 |
| Pad Chivukula Chief Scientific Officer & COO | Aug 3, 2021 | Sale(10b5-1 plan) | −10,000 | $40.07 | $400.70K | 642,548 |
| Pad Chivukula Chief Scientific Officer & COO | Apr 1, 2021 | Sale(10b5-1 plan) | −10,000 | $42.95 | $429.50K | 652,548 |
| Pad Chivukula Chief Scientific Officer & COO | Mar 1, 2021 | Sale(10b5-1 plan) | −10,000 | $54.23 | $542.30K | 662,548 |
| Pad Chivukula Chief Scientific Officer & COO | Feb 1, 2021 | Sale(10b5-1 plan) | −10,000 | $75.31 | $753.10K | 672,548 |
| Pad Chivukula Chief Scientific Officer & COO | Jan 4, 2021 | Sale(10b5-1 plan) | −10,000 | $46.40 | $464.00K | 682,548 |
| Pharmaceutical Inc. Ultragenyx Director, 10% owner | Dec 9, 2020 | Sale | −357,745 | $94.97 | $33.98M | 2,200,000 |
| Pharmaceutical Inc. Ultragenyx Director, 10% owner | Dec 8, 2020 | Sale | −442,255 | $105.54 | $46.68M | 2,557,745 |
| Pad Chivukula Chief Scientific Officer & COO | Dec 1, 2020 | Sale(10b5-1 plan) | −10,000 | $96.19 | $961.90K | 692,548 |
| Pad Chivukula Chief Scientific Officer & COO | Nov 2, 2020 | Sale(10b5-1 plan) | −10,000 | $55.28 | $552.80K | 702,548 |
| Pad Chivukula Chief Scientific Officer & COO | Oct 1, 2020 | Sale(10b5-1 plan) | −10,000 | $42.83 | $428.30K | 712,548 |
| Pad Chivukula Chief Scientific Officer & COO | Sep 3, 2020 | Sale(10b5-1 plan) | −10,000 | $45.16 | $451.60K | 722,548 |
| Keith C. Kummerfeld See Remarks | Jun 12, 2020 | Buy | +450 | $33.33 | $15.00K | 950 |
| Joseph E. Payne President and CEO, Director | Jun 10, 2020 | Buy | +1,000 | $31.69 | $31.69K | 1,475,097 |
| Andy Sassine Chief Financial Officer, Director | Jun 10, 2020 | Buy | +5,000 | $29.74 | $148.70K | 273,245 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Pad Chivukula Officer | Oct 15, 2024 | 12,000 | $249.12K | Oct 15, 2024 | FOUNDERS SHARES |
| Keith C. Kummerfeld Officer | Jun 18, 2024 | 2,000 | $64.00K | Jun 10, 2024 | STOCK OPTION EXERCISE |
| Andy Sassine Director | Jun 12, 2024 | 50,000 | $1.60M | Jun 12, 2024 | Market Purchase |
| Pad Chivukula Officer | Jun 5, 2024 | 37,000 | $1.67M | Jun 5, 2024 | Founders Shares |
| Pad Chivukula Officer | Jun 3, 2024 | 26,000 | $1.04M | Jun 3, 2024 | Founders Shares |
| Pad Chivukula Officer | Mar 19, 2024 | 26,000 | $910.00K | Mar 19, 2024 | Founders Shares |
| Pad Chivukula Officer | Oct 2, 2023 | 15,000 | $390.00K | Oct 2, 2023 | Founders Shares |
| Pad Chivukula Officer | Sep 1, 2023 | 5,000 | $155.00K | Sep 1, 2023 | FOUNDERS SHARES |
| Pad Chivukula Officer | Aug 1, 2023 | 5,000 | $175.00K | Aug 1, 2023 | Founders Shares |
| Pad Chivukula Officer | Jul 14, 2023 | 25,000 | $875.34K | Jul 14, 2023 | Founders Shares |
| C. Kummerfeld Keith Officer | Jul 14, 2023 | 6,968 | $243.88K | Jul 14, 2023 | Stock Option Exercise |
| Pad Chivukula Officer | May 11, 2023 | 7,925 | $239.68K | May 11, 2023 | Founders Shares |
| Pad Chivukula Officer | May 10, 2023 | 17,075 | $512.29K | May 10, 2023 | Founders Shares |
| C. Kummerfeld Keith Officer | Apr 17, 2023 | 6,968 | $196.34K | Apr 17, 2023 | STOCK OPTIONS |